16Oct 2025
Nemolizumab Shows Long-Term Safety and Effectiveness in Atopic Dermatitis Patients

Nemolizumab Shows Long-Term Safety and Effectiveness in Atopic Dermatitis Patients

The ARCADIA long-term extension study of over 1,900 patients reveals that nemolizumab remains safe and effective for up to 104 weeks in adolescents and adults with moderate-to-severe atopic dermatitis. The treatment led to lasting improvements in itch, sleep, and skin symptoms, with most side effects mild or moderate and no new safety concerns reported.

  • #dermatology

Like

Save

Share